Trade BioNTech BNTX

Sell
 Buy

BioNTech live chart

5m 15m 30m 1h 4h 1d 1w

Instrument Fundamentals

Weekly Search
Weekly
Daily
Date Close Change Change (%) Open High Low

BioNTech News

Emma Rose 2025 Dec 06, 00:00

Navigating the Fed Chair Challenges Under Trump's Policies

Emma Rose 2025 Dec 06, 00:00

Wall Street Banks Predict Double-Digit S&P 500 Growth in 2026 Despite AI Concerns

Emma Rose 2025 Dec 06, 00:00

Economists Expect Fed Rate Cut in December Despite Internal Divisions

Liam James 2025 Dec 06, 00:00

Key Market Risks for 2026: Insights from Apollo Global Management

Emma Rose 2025 Dec 06, 00:00

Bank of America: Fed's Outlook Could Threaten Stock Market Rally

Ghko B 2025 Dec 04, 16:00

Bitcoin price prediction: BTC/USD rebounds, is BTC expected to rise further?

Ghko B 2025 Dec 04, 16:00

Nio stock price prediction: NIO jumps today, will this rally accelerate?

Ghko B 2025 Dec 03, 16:00

Stock opportunities for 2026: TSMC Stock, CRCL Stock, IONQ Stock, NIO

Ghko B 2025 Dec 03, 16:00

Best S&P 500 ETF to buy: Vanguard S&P 500 ETF (VOO), SPY, IVV, iShares ETFs

Ghko B 2025 Dec 03, 16:00

Best CFD Brokers: Award-winning CFD Platforms, markets.com, IG, Pepperstone

Latest news

Show more
Noah Lee 2025 Dec 06, 17:50

ESMA Expansion Sparks Crypto, Fintech Slowdown Concerns in EU

Noah Lee 2025 Dec 06, 17:00

Bitcoin's 'Santa' Rally: Fed Rate Decision and 2026 Outlook

Liam James 2025 Dec 06, 12:40

Western Union Unveils Stable Card, Stablecoin Strategy to Combat Inflation

Ava Grace 2025 Dec 06, 11:50

Market Movers: Fed Rate Decision & Key Economic Data in Focus Next Week

Noah Lee 2025 Dec 06, 10:50

Central Bank Rate Decisions & Market Volatility Outlook: What to Expect

Emma Rose 2025 Dec 06, 09:40

Clear Street Prepares for IPO Amid Crypto Treasury Model Concerns

Ava Grace 2025 Dec 06, 09:30

Crypto Market Analysis and Regulatory Updates: December 6, 2024

Sophia Claire 2025 Dec 06, 08:00

Bitcoin Treasury Firms Face 'Darwinian Phase' Amid Market Shift

Info

Spread

0.6676

Spread (%)

0.6959 %

Leverage

1:10

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Markets closed

Monday

14:31 - 20:59

Tuesday

14:31-20:59

Wednesday

14:31-20:59

Thursday

14:31-20:59

Friday

14:31-20:59

Analysis and statistics

Open

---

Previous Close

---

52 Week High/Low

--- – ---

Market cap

23143837696

Shares Outstanding

240455450

Earnings Date (Next)

0000-00-00

Div Yield

2022-06-17

Ex-Dividend Date

2022-06-02

Forward annual dividend rate

0

Forward annual dividend yield

0

EPS

-2.78

Learn more about this instrument

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Related Instruments

Asset
Sell
Buy
Change (%)

Trade Now

Trade Now

Trade Now

Trade Now
View all instruments

Latest Education Articles

Show more
Ghko B 2025 Dec 04, 16:00

How to trade gold: Trading tips on gold CFDs, Short-term trades in XAU/USD

Ghko B 2025 Dec 03, 16:00

What are the most traded indices: how to trade indices CFD with markets.com?

Ghko B 2025 Dec 03, 16:00

Start investing in 2026: trader's guide, how to find the best CFD broker?

Trustpilot